Alpha Cognition
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company developing and commercializing ZUNVEYL (benzgalantamine), an FDA-approved oral prodrug therapy for mild-to-moderate Alzheimer's disease, targeting US long-term care facilities through a 60-person field sales force and Medicare Part D coverage of approximately 45 million lives.
- Company typePublic
- Founded2020
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alpha Cognition does
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with US operations based in Grapevine, Texas. The company develops treatments for neurodegenerative diseases with limited or no approved therapeutic options, focused initially on Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI). Its flagship commercial product, ZUNVEYL (benzgalantamine), received FDA approval on July 29, 2024 for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults and was commercially launched in the United States in March 2025.
The company's core technology is a proprietary prodrug platform built around ALPHA-1062 (benzgalantamine), a new chemical entity that converts to galantamine in vivo. The prodrug is engineered to reduce gastrointestinal absorption of the active drug, addressing the tolerability issues that cause approximately 55% of patients on conventional acetylcholinesterase inhibitors to discontinue therapy within one year. Beyond acetylcholinesterase inhibition, benzgalantamine also binds neuronal nicotinic receptors including the alpha-7 subtype, providing a dual mechanism of action with potential pro-cognitive effects. The platform is being extended into sublingual, enteric-coated, and intranasal formulations, and a separate pipeline asset, ALPHA-602 (Progranulin), has received FDA Orphan Drug Designation for ALS.
Alpha Cognition's business model combines direct US commercial sales with international licensing. In the United States, a 60-person field sales team targets the long-term care market — primarily nursing homes and assisted living facilities — supported by Medicare Part D contracts with two major pharmacy benefit managers covering approximately 45 million lives without prior authorization requirements. As of Q1 2026, the company had reached 2,502 unique nursing homes, 1,060 active prescribers, and dispensed 6,054 bottles of ZUNVEYL during the quarter. Internationally, Alpha Cognition executed a $44 million exclusive licensing agreement with China Medical System (CMS Pharma) for development and commercialization of ZUNVEYL in China, where the NDA was accepted for review in July 2025. Revenue is generated through prescription product sales (net product revenue of $6.8M in FY2025) and licensing/royalty streams ($3.4M in FY2025), with total FY2025 revenue of $10.2 million.
Alpha Cognition firmographics
Firmographics- Name
- Alpha Cognition
- Legal name
- Alpha Cognition Inc.
- Website
- https://alphacognition.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company developing and commercializing ZUNVEYL (benzgalantamine), an FDA-approved oral prodrug therapy for mild-to-moderate Alzheimer's disease, targeting US long-term care facilities through a 60-person field sales force and Medicare Part D coverage of approximately 45 million lives.
- Ownership category
- akta.pro rank
Alpha Cognition industry classification
Industry- Product category
- Alzheimer's Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)
Keywords
Where Alpha Cognition is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Alpha Cognition business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Marketing or Sales, Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- ZUNVEYL Product Sales: Net product revenue from sales of FDA-approved ZUNVEYL (benzgalantamine) for Alzheimer's disease. Q1 2026 revenue of $3.5 million representing 40% sequential growth. FY2025 total revenue of $10.2 million including $6.8 million net product revenue and $3.4 million licensing revenue. Bottles dispensed metric used to track real-world product usage.
- Licensing Revenue - China Medical System: $44 million exclusive licensing agreement with China Medical System for development and commercialization of ZUNVEYL in China. CMS Pharma NDA accepted in China in July 2025. Expected two strategic product approvals in Asia via CMS Pharma in 2026.
- CMS Pharma Collaboration Licensing: Licensing revenue from collaboration with CMS Pharma, contributing $3.4 million to FY2025 total revenue of $10.2 million.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription pharmaceutical product with no publicly disclosed list price |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Alpha Cognition product offering
Product offeringCore offering
Alpha Cognition develops and commercializes ZUNVEYL (benzgalantamine), an FDA-approved oral prodrug of galantamine indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. The proprietary prodrug technology is designed to reduce gastrointestinal side effects versus conventional AChEIs and addresses the 55% one-year discontinuation rate of existing Alzheimer's medications. The pipeline includes ALPHA-1062 in multiple formulations (sublingual, enteric-coated, intranasal) for Alzheimer's and traumatic brain injury, and ALPHA-602 (Progranulin) for ALS.
Product overview
Alpha Cognition is a commercial-stage biopharmaceutical company with ZUNVEYL as its FDA-approved flagship product for Alzheimer's disease, launched commercially in March 2025. The pipeline includes ALPHA-1062, a prodrug of galantamine in development as multiple formulations (sublingual, enteric-coated, intranasal) for Alzheimer's and mild traumatic brain injury, and ALPHA-602 (Progranulin) for ALS. The company focuses on neurodegenerative diseases with treatments addressing unmet needs through novel drug delivery technologies.
Differentiator
Problem solved
Functional benefit
Brands
- ZUNVEYL: FDA-approved oral therapy (benzgalantamine) for mild-to-moderate Alzheimer's disease
- ALPHA-1062
- ALPHA-602 (Progranulin)
Products and services
- ZUNVEYL (benzgalantamine) FDA-approved oral cholinesterase inhibitor (prodrug of galantamine) indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. Designed with a differentiated metabolic profile that reduces gastrointestinal exposure, addressing tolerability issues that cause 55% of patients to discontinue existing Alzheimer's medications. Features dual mechanism of action combining acetylcholinesterase inhibition with neuronal nicotinic receptor binding including the alpha-7 subtype.
- ALPHA-1062 (pipeline) Patented new chemical entity prodrug of galantamine being developed in sublingual tablet, enteric-coated tablet, and intranasal formulations for Alzheimer's disease and cognitive impairment with mild traumatic brain injury. Demonstrated 90%+ reduction in GI side effects compared to conventional galantamine in Phase 1 studies. Intranasal delivery achieves 10-fold higher brain concentration of galantamine versus oral administration.
- ALPHA-602 (Progranulin) Protein therapeutic for amyotrophic lateral sclerosis (ALS) with neuroprotective properties. Regulates cell survival, lysosomal function, and microglial responses. The FDA granted Orphan Drug Designation for ALS treatment.
Quantifiable outcome
- 40% sequential revenue growth Q4 2025 to Q1 2026, from $2.5M to $3.5M
- +4 more outcomes
Companies that use Alpha Cognition
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles3 records
Alpha Cognition technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Alpha Cognition partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Clinical Research Sites (BEACON Study)minorPhase 4 BEACON real-world effectiveness study evaluating ZUNVEYL in nursing home patients. Study enrolled approximately 200 patients across multiple clinical sites with 21 investigators. Top-line results announced June 2026 showing positive outcomes.
- China Medical System (CMS Pharma)core$44 million exclusive licensing agreement for development and commercialization of ZUNVEYL (benzgalantamine) in China. CMS Pharma NDA accepted in China for review in July 2025. Expected two strategic product approvals in Asia via CMS Pharma in 2026.
- LinicalcoreStrategic partnership for regulatory consulting and clinical trial support for Alpha-1062 in US and Japan markets. Services include regulatory consulting, clinical trial support, post-marketing pharmacovigilance, medical information and safety support. Linical is a mid-size CRO with significant footprint in Japan and North America.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Alpha Cognition competitors and assessment
Company assessmentBroad incumbents
- Eisai: Co-developer of LEQEMBI with Biogen, the leading disease-modifying Alzheimer's therapy. Comparable as a global pharma with a major Alzheimer's commercial franchise and overlapping target prescriber base.
- Lundbeck: Global CNS-focused pharmaceutical company with established Alzheimer's franchise (donepezil legacy) and broader neurology pipeline. Comparable commercial-channel overlap in long-term care and psychiatry prescribers.
- Biogen: Major biopharmaceutical company with leading Alzheimer's franchise including ADUHELM and LEQEMBI (with Eisai), plus established neurology infrastructure. Comparable as the leading Alzheimer's-focused commercial-stage biopharma with extensive long-term care reach.
- Intra-Cellular Therapies: Commercial-stage CNS biopharma (CAPLYTA/lumateperone) with growing long-term care channel presence. Comparable as a CNS-focused specialty pharma that scaled from a single approved product to broad commercial uptake.
- Otsuka Pharmaceutical: Global pharma with established CNS franchise including REXULTI and ABILIFY and significant US long-term care presence. Comparable prescriber overlap in nursing home psychiatry and Alzheimer's-related behavioral symptoms.
- ACADIA Pharmaceuticals: Commercial-stage CNS biopharma with approved therapy (pimavanserin/NUPLAZID) for Parkinson's disease psychosis and a pipeline spanning Alzheimer's psychosis and Rett syndrome. Directly comparable commercial-stage CNS specialty pharma footprint.
Emerging players
- Sage Therapeutics: CNS-focused biopharma developing therapies for depression, epilepsy, and neurodegenerative disorders. Comparable as a CNS-focused biopharma pursuing novel mechanisms in underserved neurological indications.
- Axsome Therapeutics: Commercial-stage CNS biopharma with Auvelity (dextromethorphan/bupropion) for depression and growing neurology presence. Comparable trajectory: built CNS commercial channel around novel differentiated mechanisms, scaled via specialty sales force.
Direct peers
- Anavex Life Sciences: Clinical-stage biopharma developing treatments for Alzheimer's disease, Rett syndrome, and other neurodegenerative diseases. Comparable as a small-cap CNS drug developer pursuing differentiated mechanisms in memory/cognitive disorders.
- Cassava Sciences: Clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease. Comparable as a small-cap CNS-focused company targeting the same disease state with a novel mechanism attempting to differentiate from established AChEIs.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Alpha Cognition social profiles
Digital presenceAlpha Cognition financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alpha Cognition leadership team
Management profileNumber of profiles
Profiles7 records
Alpha Cognition funding detail
Funding detailFunding overview
Funding rounds8 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alpha Cognition M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alpha Cognition
What does Alpha Cognition do?
Alpha Cognition develops and commercializes ZUNVEYL (benzgalantamine), an FDA-approved oral prodrug of galantamine indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. The proprietary prodrug technology is designed to reduce gastrointestinal side effects versus conventional AChEIs and addresses the 55% one-year discontinuation rate of existing Alzheimer's medications. The pipeline includes ALPHA-1062 in multiple formulations (sublingual, enteric-coated, intranasal) for Alzheimer's and traumatic brain injury, and ALPHA-602 (Progranulin) for ALS.
Is Alpha Cognition a public or private company?
Alpha Cognition is a public company. It is classified as public and is currently operating.
When was Alpha Cognition founded?
Alpha Cognition was founded in 2020. It employs 11 to 50 people.
Where is Alpha Cognition based?
Alpha Cognition is headquartered in Vancouver, Canada, in the North America region.
How does Alpha Cognition make money?
Three revenue lines are on record. ZUNVEYL Product Sales are the primary driver. The others are licensing Revenue - China Medical System and CMS Pharma Collaboration Licensing.
Who are Alpha Cognition's main competitors?
Broad incumbents on record are Eisai, Lundbeck, Biogen, Intra-Cellular Therapies, Otsuka Pharmaceutical and ACADIA Pharmaceuticals. Emerging players are Sage Therapeutics and Axsome Therapeutics. Direct peers are Anavex Life Sciences and Cassava Sciences.
Does Alpha Cognition have an API?
No public API is recorded for Alpha Cognition.
What industry is Alpha Cognition in?
Alpha Cognition's product category is Alzheimer's Disease Therapeutics. Its primary akta.pro industry code is HLAKAIAH, Cognitive & Behavioral Neurology (Dementia/Memory Disorders). Its NAICS code is 541714 and its SIC code is 2833.